Piedmont Healthcare Inc

1. Novartis Pharmaceuticals Corporation $820,284 8 payments
2. Abbott Laboratories $727,986 131 payments
3. Edwards Lifesciences Corporation $706,898 27 payments
4. United Therapeutics Corporation $603,732 78 payments
5. Moderna TX, Inc. $574,023 28 payments
6. Biosense Webster, Inc. $366,912 25 payments
7. Janssen Research & Development, LLC $278,481 74 payments
8. GT Medical Technologies, Inc $165,442 32 payments
9. Boston Scientific Corporation $150,915 3 payments
10. Roche Products Limited $122,001 15 payments

1. A Two-Year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 MG S.C. Secukinumab Versus Placebo, in Combination With Soc Therapy, in Patients With Active Lupus Nephritis $726,490 5 payments
2. A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls $574,023 28 payments
3. Expedite: A 16-Week Multicenter Open-Label Study of Remodulin Induction Followed By Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension $322,646 21 payments
4. Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System $290,325 17 payments
5. Evoque Tr 2019-06 $288,750 4 payments
6. TRISCEND II Pivotal (2020-05) $164,104 2 payments
7. Resolve Af $150,915 3 payments
8. Cephea Early Feasibility Study $125,365 4 payments
9. NCT05932615--ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation $119,124 5 payments
10. Adapt - A Patient Registry of the Real-World Use of Orenitram $109,940 23 payments

1. Non-patient care $23,670 7 payments
2. Other $3,300 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.